PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier.
BACKGROUND
Blood-brain barrier (BBB) dysfunction/disruption followed by leukocyte infiltration into the brain causes neuroinflammation and contributes to morbidity in multiple sclerosis, encephalitis, traumatic brain injury, and stroke. The identification of pathways that decreases the inflammatory potential of leukocytes would prevent such injury. Poly(ADP-ribose) polymerase 1 (PARP) controls various genes via its interaction with myriad transcription factors. Selective PARP inhibitors have appeared lately as potent anti-inflammatory tools. Their effects are outside the recognized PARP functions in DNA repair and transcriptional regulation. In this study, we explored the idea that selective inhibition of PARP in leukocytes would diminish their engagement of the brain endothelium.


METHODS
Cerebral vascular changes and leukocyte-endothelium interactions were surveyed by intravital videomicroscopy utilizing a novel in vivo model of localized aseptic meningitis when TNFα was introduced intracerebrally in wild-type (PARP+/+) and PARP-deficient (PARP-/-) mice. The effects of selective PARP inhibition on primary human monocytes ability to adhere to or migrate across the BBB were also tested in vitro, employing primary human brain microvascular endothelial cells (BMVEC) as an in vitro model of the BBB.


RESULTS
PARP suppression in monocytes diminished their adhesion to and migration across BBB in vitro models and prevented barrier injury. In monocytes, PARP inactivation decreased conformational activation of integrins that plays a key role in their tissue infiltration. Such changes were mediated by suppression of activation of small Rho GTPases and cytoskeletal rearrangements in monocytes. In vitro observations were confirmed in vivo showing diminished leukocyte-endothelial interaction after selective PARP suppression in leukocytes accompanied by BBB protection. PARP knockout animals demonstrated a substantial diminution of inflammatory responses in brain microvasculature and a decrease in BBB permeability.


CONCLUSIONS
These results suggest PARP inhibition in leukocytes as a novel approach to BBB protection in the setting of endothelial dysfunction caused by inflammation-induced leukocyte engagement.
Department of Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, 19140, USA. srom@temple.edu.|Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA. srom@temple.edu.
Slava
S
Rom
Department of Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, 19140, USA.
Viviana
V
Zuluaga-Ramirez
Department of Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, 19140, USA.
Nancy L
NL
Reichenbach
Department of Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, 19140, USA.
Holly
H
Dykstra
Department of Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, 19140, USA.
Sachin
S
Gajghate
Laboratory of Cardiovascular Physiology and Tissue Injury, National Institutes of Health/NIAAA, Bethesda, MD, 20852, USA.
Pal
P
Pacher
Department of Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, 19140, USA. yuri.persidsky@tuhs.temple.edu.|Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA. yuri.persidsky@tuhs.temple.edu.
Yuri
Y
Persidsky
Actin cytoskeleton; LFA-1; Leukocyte-endothelial interaction; PARP-1; VLA-4
Circ Res. 2006 Mar 31;98(6):757-67
16574916
Biochem J. 2000 Mar 15;346 Pt 3:641-9
10698690
Methods Mol Biol. 2011;780:463-89
21870278
J Leukoc Biol. 2003 Jan;73(1):30-48
12525560
Front Immunol. 2012 Aug 02;3:242
22876249
J Exp Med. 1997 Aug 18;186(4):517-27
9254650
J Cell Biol. 2005 Dec 19;171(6):1073-84
16365170
J Biol Chem. 2009 May 22;284(21):14337-46
19251697
Stroke. 2006 Feb;37(2):291-3
16410468
Trends Endocrinol Metab. 2015 Feb;26(2):75-83
25497347
Oncotarget. 2015 Feb 28;6(6):3825-39
25686825
Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):711-7
18239155
Curr Neuropharmacol. 2009 Mar;7(1):65-74
19721819
Biochim Biophys Acta. 2016 Mar;1862(3):472-82
26454208
Nat Rev Neurol. 2015 Sep;11(9):524-35
26303850
J Immunol. 2008 Feb 1;180(3):1854-65
18209083
Hepatology. 2014 May;59(5):1998-2009
24089324
Expert Opin Ther Targets. 2015;19(9):1149-52
26212149
Microcirculation. 2000 Jun;7(3):201-14
10901499
J Neurosci Res. 2005 Jul 15;81(2):190-8
15931673
Am J Pathol. 2015 Jun;185(6):1548-51
25963553
Am J Pathol. 2013 Nov;183(5):1548-58
24055259
Mol Immunol. 2015 Feb;63(2):394-405
25304310
Biochem Pharmacol. 2003 Apr 15;65(8):1373-82
12694878
Atherosclerosis. 2005 Nov;183(1):1-16
15982657
Brain Res. 2002 Apr 5;932(1-2):110-9
11911867
Stroke. 2009 May;40(5):1849-57
19265055
J Cereb Blood Flow Metab. 2014 Oct;34(10):1573-84
25074747
Arch Neurol. 2002 Mar;59(3):391-7
11890842
Curr Opin Pharmacol. 2008 Feb;8(1):96-103
18032109
Mech Ageing Dev. 2015 Mar;146-148:53-64
25881554
Physiol Rev. 2007 Jan;87(1):315-424
17237348
Nat Immunol. 2009 Feb;10(2):185-94
19136961
Cell Signal. 2013 Feb;25(2):457-69
23153585
J Leukoc Biol. 2001 Aug;70(2):329-34
11493627
J Biol Chem. 2004 Apr 16;279(16):16194-205
14960575
Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H659-66
15044192
J Cereb Blood Flow Metab. 2015 Jan;35(1):28-36
25248836
Nat Rev Immunol. 2011 Jun;11(6):416-26
21597477
Am J Physiol Cell Physiol. 2003 Aug;285(2):C250-2
12842833
Fluids Barriers CNS. 2015 Oct 27;12:24
26507826
Front Microbiol. 2015 Aug 25;6:878
26379653
J Cereb Blood Flow Metab. 2002 Jan;22(1):39-49
11807392
Acta Crystallogr D Biol Crystallogr. 2014 Oct;70(Pt 10):2740-53
25286857
Nat Rev Cancer. 2010 Apr;10 (4):293-301
20200537
J Cereb Blood Flow Metab. 2007 Jul;27(7):1318-26
17213862
Fluids Barriers CNS. 2012 Nov 09;9(1):23
23140302
J Immunol. 2014 Jan 1;192(1):324-37
24259506
FEBS Lett. 2011 Dec 1;585(23):3770-80
21550344
Nat Rev Drug Discov. 2005 May;4(5):421-40
15864271
Free Radic Biol Med. 2014 Oct;75 Suppl 1:S19
26461300
J Cereb Blood Flow Metab. 2015 Dec;35(12 ):1957-65
26126865
Am J Pathol. 2011 Mar;178(3):946-55
21356345
Immunity. 2004 Apr;20(4):393-406
15084269
J Neuroimmune Pharmacol. 2006 Sep;1(3):223-36
18040800
Oxid Med Cell Longev. 2015;2015:725370
26106458
PLoS One. 2014 May 13;9(5):e97378
24824795
J Leukoc Biol. 2010 May;87(5):779-89
20130219
Arterioscler Thromb Vasc Biol. 2004 May;24(5):824-33
14976004
Mult Scler. 2011 Jul;17 (7):794-807
21343230
Nat Immunol. 2009 Sep;10 (9):958-64
19684606
Nat Protoc. 2010 Jul;5(7):1265-72
20595955
Cytokine. 2014 Aug;68(2):76-85
24845796
J Immunol. 2000 Sep 15;165(6):3375-83
10975856
Neuroscience. 2009 Feb 6;158(3):972-82
18824084
J Neurosci. 2012 Mar 21;32(12 ):4004-16
22442067
Blood. 2011 Mar 24;117(12):3331-42
21200022
Nat Biotechnol. 2012 Feb 19;30(3):283-8
22343925
Am J Pathol. 2012 Oct;181(4):1414-25
22863953
Br J Pharmacol. 2012 Apr;165(8):2462-78
21449982
Acta Crystallogr F Struct Biol Commun. 2014 Sep;70(Pt 9):1143-9
25195882
J Leukoc Biol. 2008 Jan;83(1):1-12
17906117
Neuron. 2014 May 7;82(3):603-17
24746419
J Neuroinflammation. 2012 Feb 15;9:31
22335939
Hum Immunol. 2012 May;73(5):439-47
22391342
Microcirculation. 2006 Sep;13(6):439-56
16864411
J Neurotrauma. 2010 Jun;27(6):1069-79
20380552
Brain Behav. 2014 Jul;4(4):552-65
25161822
Pharmacol Rev. 2002 Sep;54(3):375-429
12223530
Am J Respir Crit Care Med. 2001 Jan;163(1):210-7
11208648
Nat Rev Immunol. 2004 Feb;4(2):110-22
15040584
Curr Neurol Neurosci Rep. 2015 Apr;15(4):17
25716012
Nat Protoc. 2014 Nov;9(11):2515-38
25275789
J Neuroinflammation. 2015 Dec 04;12 :229
26637332
Anticancer Res. 2009 Jan;29(1):119-23
19331140
Arch Biochem Biophys. 1997 Mar 15;339(2):267-74
9056258